PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates

Nobuyuki Shimizu; Tomoko Asatsuma-Okumura; Junichi Yamamoto; Yuki Yamaguchi; Hiroshi Handa; Takumi Ito

doi:10.1038/s42003-021-02801-y

Communications Biology (Nov 2021)

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates

Nobuyuki Shimizu,
Tomoko Asatsuma-Okumura,
Junichi Yamamoto,
Yuki Yamaguchi,
Hiroshi Handa,
Takumi Ito

Affiliations

Nobuyuki Shimizu: Department of Chemical Biology, Tokyo Medical University
Tomoko Asatsuma-Okumura: Department of Chemical Biology, Tokyo Medical University
Junichi Yamamoto: School of Life Science and Technology, Tokyo Institute of Technology
Yuki Yamaguchi: School of Life Science and Technology, Tokyo Institute of Technology
Hiroshi Handa: Department of Chemical Biology, Tokyo Medical University
Takumi Ito: Department of Chemical Biology, Tokyo Medical University

DOI: https://doi.org/10.1038/s42003-021-02801-y
Journal volume & issue: Vol. 4, no. 1
pp. 1 – 11

Abstract

Read online

Shimizu et al. identify PLZF/ZBTB16 and its fusion proteins as pomalidomide-dependent neosubstrates of the cereblon E3 ligase. The authors also report that pomalidomide induces their degradation and thereby exerts its anti-cancer effect in leukemic cells expressing the fusion proteins.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal